Business
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., May 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/0df4a21c0ca6d4456dece915737ab792"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7SNOMesmcyHaOL.fJcUb8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0df4a21c0ca6d4456dece915737ab792","width":960,"height":311},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/B1JEBOkoKu._h38InfU_tQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0df4a21c0ca6d4456dece915737ab792","width":640,"height":207},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PFZD_umfmD7gX9yHD6XQVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0df4a21c0ca6d4456dece915737ab792","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated –","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"– New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention –","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"– Closed $120 million PIPE in March 2026; cash balance of approximately $264 million expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207 –","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 13, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.","length":402,"tagName":"p"},{"type":"text","content":""2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b trial of ALTO-207 in TRD," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "ALTO-207 is supported by one of the largest independently validated efficacy signals reported in TRD, and...